UNSPSC 51314351: Chlorpheniramine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314351 Chlorpheniramine/phenylpropanolamine is a Commodity code that in recent state and local procurement shows activity dominated by broader pharmaceutical and drug-management procurements rather than this specific antihistamine compound. State and local governments soliciting under this code are primarily health departments, county health systems, and cooperative purchasing alliances procuring generic pharmaceuticals, over-the-counter products, and opioid-management supplies such as naloxone and drug deactivation systems. Issuing bodies include county health departments (such as Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work encompasses supply agreements for generic multi-source drugs and OTC inventory, direct-to-manufacturer pharmacy initiatives, and specialized emergency-response medications tied to public health and community safety programming.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct state-pharmacy-manufacturer relationships; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with awards effective July 1, 2026, a two-year term, and evaluation weighted 75 percent on price competitiveness. Vendors pursuing these opportunities typically must demonstrate cGMP and DSCSA compliance, maintain relationships with authorized wholesalers or direct-contract capacity, provide comprehensive insurance coverage, and submit pricing through state e-procurement portals.